Skip to content
Lower risk Drug recall · FDA · Published August 22, 2024

ProRx Tirzepatide Vials Recall: Lack of Sterility Assurance

ProRx recalls compounded Tirzepatide injections due to lack of sterility assurance. Affected vials may cause infections if used. Contact ProRx for details.

🇺🇸 FDA recall #D-0651-2024DrugProRx ›
Take action

Contact the company

Recalling firmProRx LLC619 Jeffers Cir · Exton, PA 19341-2540
✎ GovInfoNow plain-language explainer

ProRx is recalling compounded Tirzepatide injections because they lack sterility assurance. Using these vials could lead to infections if they are not properly sterilized. Read more at govinfonow.com/recall/32553-prorx-tirzepatide-vials-recall-lack-of-sterility-assurance.

Source Summary by GovInfoNow · govinfonow.com/recall/32553-prorx-tirzepatide-vials-recall-lack-of-sterility-assurance · Updated August 17, 2026 · FDA enforcement record: FDA #D-0651-2024

Cite this page

“ProRx Tirzepatide Vials Recall: Lack of Sterility Assurance.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/32553-prorx-tirzepatide-vials-recall-lack-of-sterility-assurance. Based on FDA recall #D-0651-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0651-2024%22&limit=1).

The FDA announced on Aug. 22, 2024, that ProRx LLC is recalling Tirzepatide multidose injection vials due to a lack of assurance of sterility. According to the FDA, owners should stop using the product immediately.

How to tell if you have it

  • Brand: ProRx
  • Product: Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials
  • NDC: 84139-210-01
  • Lot #: ProRx040924-1
  • BUD: 10/08/2024

The hazard

The recall addresses a lack of assurance of sterility in the compounded prescription product. The FDA classified this as a Class II recall.

Context

GovInfoNow's records show ProRx LLC has one other recall on record since Oct. 15, 2025, for Semaglutide Injection due to a lack of assurance of sterility. Other recent recalls of similar products include New Life Pharma Tirzepatide Inj 15mg Vial Recall (Feb. 26, 2026), New Life Pharma Tirzepatide 10mg Vial Recall (Feb. 26, 2026), and Reliance Pemetrexed Injection Recall (June 24, 2026).

How to tell if you have this one

Check for vials labeled 'Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection' compounded by ProRx. The lot number is ProRx040924-1 with a best use date of 10/08/2024.

  • Brand
    ProRx
  • Category
    Drug
FDA recall event · 7 products

All 7 products in this recall

FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.

  • Classification
    Class II
  • Status
    Ongoing
  • Distribution
    Nationwide in the USA
Recall numberProduct, codes & lotsQuantity
D-0650-2024Semaglutide, 2 mL (2.5mg/mL), Compounded RX Product, Multidose SC inj, glass vial, ProRx, 267-565-7008, NDC 84139-225-01; Lot #: ProRx031924, BUD 09/18/2024 ProRx032624, BUD 09/25/2024 ProRx041324, BUD 10/12/20242,490 vials
D-0651-2024Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials, Compounded Rx Product, ProRx 267-565-7008, NDC 84139-210-01; Lot # ProRx040924-1, BUD 10/08/202437 vials
D-0652-2024SEMAGLUTIDE 5mg/2mL (2.5mg/mL), Rx Only 2 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX Exton, PA19341, NDC 84139-225-01; Lot #: ProRx052424, BUD 11/23/2024 ProRx060724, BUD 12/06/2024 ProRx061124, BUD 12/10/2024 ProRx061924, BUD 12/18/20248,396 vials
D-0653-2024SEMAGLUTIDE 10mg/4mL (2.5mg/mL), 4 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX Exton, PA19341, NDC 84139-225-04; ProRx061424, BUD 12/13/20241,960 vials
D-0654-2024Semaglutide / Cyanocobalamin Injection: 2.5/0.5 mg/mL, 2 mL Multiple Dose Vial, Compounded Rx Product, ProRX 267-565-7008, NDC 84139-225-02; Lot # ProRx031924-1, BUD 09/18/2024500 vials
D-0655-2024TIRZEPATIDE 20 mg/2mL (10/mg/mL), Rx Only, 2mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341, NDC 84139-210-01; Lot # ProRx051424, BUD 11/13/20241,489 vials
D-0656-2024TIRZEPATIDE 60 mg/3mL (20/mg/mL), Rx Only, 3mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341, NDC 84139-210-02; Lot# ProRx052224, BUD 11/21/2024 ProRx061024, BUD 12/09/20241,732 vials
Based on the official FDA remedy

What to do — step by step

  1. Check Vial Label

    Look for the product name and lot number on the vial to confirm it matches the recalled items.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA published this recall 20 days after the firm started it.

1. Firm started the recall: Aug 22, 202412. FDA classified it Class II: Sep 5, 202423. Published in FDA’s Enforcement Report: Sep 11, 202432024
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0651-2024 (August 22, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0651-2024 to see it in context.
  • Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA